Acura Pharmaceuticals

Executive Summary

Acura Pharmaceuticals is a specialty pharmaceutical company focused on developing abuse-deterrent formulations of widely used medications, particularly opioid painkillers and pseudoephedrine products. The company's proprietary technology platforms—LIMITX, AVERSION, and IMPEDE—are designed to prevent tampering and misuse via oral overdose, snorting, injection, or conversion into illicit drugs. Acura's commercial and development-stage products aim to maintain therapeutic efficacy while reducing abuse potential. As a private company, Acura's progress is measured by partnerships, technology licensing, and regulatory milestones. Recent trends in opioid abuse prevention and FDA guidance on abuse-deterrent formulations create a favorable environment for Acura's technologies. However, the company faces competition from larger pharmaceutical firms developing similar technologies. Acura's ability to secure partnerships or advance its pipeline will be key to its growth.

Upcoming Catalysts (preview)

• Q2 2026FDA filing or update on LIMITX-based opioid product40% success
• Q3 2026New partnership or licensing deal for AVERSION technology50% success
• Q1 2027Regulatory progress on IMPEDE for pseudoephedrine products45% success